The negative predictive value of D-dimer on the risk of recurrent venous thromboembolism in patients with multiple previous events: a prospective cohort study (the PROLONG PLUS study)

Am J Hematol. 2012 Jul;87(7):713-5. doi: 10.1002/ajh.23198. Epub 2012 Apr 10.

Abstract

The optimal duration of anticoagulation after recurrent venous thromboembolism(VTE) is poorly established [1,2]. Recent studies suggested that D-dimer may identify patients at low risk of recurrence after a first VTE [3,4]. In a pilot, prospective, cohort study we aimed to assess the negative predictive value of D-dimer in patients with recurrent VTE. Patients with negative D-dimer while on treatment stopped anti coagulation and underwent repeated testing after 7, 15, and 30 days; treatment was resumed if D-dimer turned positive and permanently stopped if it remained negative. The study was interrupted after the enrolment of 75 patients. At that time, treating physicians decided treatment resumption in 12.2% of the patients, but the majority of events were distal or superficial vein thromboses. The rate of objectively documented recurrent proximal deep vein thrombosis (DVT) and/or pulmonary embolism (PE) was 2.56% (95% CI 0.13, 15.07%) in the 39 patients with persistently negative D-dimer at 30 days, for an annual incidence of VTE of 5.65 events/100 patient/years. These preliminary findings suggest that negative D-dimer may identify patients with history of previous VTE at low risk of recurrences, but this approach should be tested in larger trials in highly selected patients.

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Anticoagulants / administration & dosage
  • Anticoagulants / therapeutic use*
  • Cohort Studies
  • Drug Monitoring
  • Early Termination of Clinical Trials
  • Female
  • Fibrin Fibrinogen Degradation Products / analysis*
  • Follow-Up Studies
  • Humans
  • Incidence
  • Italy / epidemiology
  • Male
  • Middle Aged
  • Pilot Projects
  • Pulmonary Embolism / epidemiology
  • Pulmonary Embolism / etiology
  • Risk Factors
  • Secondary Prevention
  • Venous Thromboembolism / blood*
  • Venous Thromboembolism / drug therapy*
  • Venous Thromboembolism / physiopathology
  • Venous Thromboembolism / prevention & control
  • Venous Thrombosis / epidemiology
  • Venous Thrombosis / etiology
  • Vitamin K / antagonists & inhibitors

Substances

  • Anticoagulants
  • Fibrin Fibrinogen Degradation Products
  • fibrin fragment D
  • Vitamin K